In support of this notion, combinations of SFK and MEK inhibitors exhibited synergistic effects on PDAC patient-derived cell lines and xenografts [179] and other KRAS-mutant cancer models both in vitro and in vivo [180]. This evidence concerns the gene KRAS and cancer.